Edition:
United States

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

4.18USD
11:49am EST
Change (% chg)

$0.01 (+0.24%)
Prev Close
$4.17
Open
$4.21
Day's High
$4.21
Day's Low
$4.07
Volume
8,481
Avg. Vol
97,658
52-wk High
$22.16
52-wk Low
$3.21

Select another date:

Fri, Dec 8 2017

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

BRIEF-Akari Therapeutics proposes public offering of ADS

* Akari Therapeutics announces proposed public offering of American Depositary Shares Source text for Eikon: Further company coverage:

BRIEF-Akari Therapeutics announces further clinical progress

* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH​

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

BRIEF-Akari Therapeutics appoints David Horn Solomon as CEO

* Akari Therapeutics announces appointment of David Horn Solomon as CEO

BRIEF-Akari Therapeutics PLC files for mixed shelf of up to $100 mln

* Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing Source text: (http://bit.ly/2vLqRqG) Further company coverage:

Select another date: